SCHEMBL3900288

SCHEMBL3900288

O=C(O)c1cc(Oc2cccc(F)c2F)ccc1[N+](=O)[O-]

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.56
MEN1 O00255 1/20 0.56
TTR P02766 1/20 0.56
PPOX P50336 1/20 0.56
KMT2A Q03164 1/20 0.56
PYGL P06737 7/20 0.52
PYGM P11217 6/20 0.52
DTYMK P23919 1/20 0.45
HPSE Q9Y251 1/20 0.44
F10 P00742 1/20 0.43
KDM4E B2RXH2 2/20 0.42
POLB P06746 1/20 0.42
HSPB1 P04792 3/20 0.41
AKR1B10 O60218 1/20 0.40
AKR1B1 P15121 1/20 0.40
AKR1C4 P17516 1/20 0.40
AKR1C3 P42330 1/20 0.40
AKR1C2 P52895 1/20 0.40
AKR1C1 Q04828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3888921 0.84 TDP1 (0.60) TDP1MEN1TTRPPOXKMT2A
SCHEMBL10784715 0.83 TDP1 (0.58) TDP1MEN1TTRPPOXKMT2A
SCHEMBL27994019 0.83 PYGM (0.54) TDP1PYGLPYGMHPSEKDM4E
SCHEMBL3890179 0.81 TDP1 (0.56) TDP1MEN1TTRPPOXKMT2A
SCHEMBL16792652 0.81 HSPB1 (0.44) TDP1MEN1KMT2APYGLPYGM
SCHEMBL16792426 0.81 MEN1 (0.47) TDP1MEN1KMT2AF10POLB
SCHEMBL31118239 0.80 MEN1 (0.55) TDP1MEN1TTRPPOXKMT2A
SCHEMBL80744 0.80 TDP1 (0.67) TDP1MEN1TTRPPOXKMT2A
SCHEMBL16792585 0.80 ALDH1A1 (0.49) TDP1MEN1KMT2AF10HSPB1
SCHEMBL706437 0.80 HPSE (0.51) TDP1MEN1TTRPPOXKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572783-B2 Obesity; N-(1-benzyl-piperidin-4-yl)-2-(2,5-dioxo-7-phenoxy-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl)-3-methyl-butyramide; modulators of ghrelin receptor (GHSR) AMGEN INC. (US) 2009-08-11 US disclosed
EP-1784390-A2 SUBSTITUTED BENZOFUSED HETEROCYCLES Amgen Inc. (US) 2007-05-16 EP disclosed
US-20060199796-A1 Substituted benzofused heterocycles AMGEN INC. (US) 2006-09-07 US disclosed
WO-2006020959-A2 SUBSTITUTED BENZOFUSED HETEROCYCLES AMGEN INC. (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199796-A1 Substituted benzofused heterocycles GPR119, SDHA, OGDH TDP1 3707/4885MEN1 1909/4885TTR 4598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.